Rapid Influenza Diagnostic Tests Market Segmented By Immunochromatographic Assays, Immunofluorescence Assays, Nucleic Acid Amplification Test principle with Influenza A Test, Influenza B Test, Influenza A+B Test Type by Throat Swab, Nasal Wash, Nasopharyngeal Aspirate Sample Type
Industry: Healthcare
Published Date: December-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 242
Report ID: PMRREP31040
Worldwide revenue from the rapid influenza diagnostic tests market was about US$ 904.2 Mn in 2024, with the global market estimated to surge ahead at a CAGR of 8.4% to reach a valuation of US$ 2.4 Bn by the end of 2033.
| Attributes | Key Insights |
|---|---|
|
Market Size (2024) |
US$ 904.2 Mn |
|
Projected Market Value (2033) |
US$ 2.4 Bn |
|
Global Market Growth Rate (2024-2033) |
8.6% CAGR |
|
Market Share of Top 5 Countries |
56.0% |
As assessed by Persistence Market Research, influenza A+B test segment is expected to hold a largest market value of US$ 832.6 Mn by 2023. Overall, rapid influenza diagnostic tests market sales account for approximately 3.3% revenue share in the global rapid test market, which was valued at around US$ 28.5 Bn at the end of 2022.
The global market for rapid influenza diagnostic tests recorded a historic CAGR of 7.6% in the last 9 years from 2013 to 2024.
Globally, there is a greater demand for efficient diagnostic methods due to the rising prevalence of influenza. The general population is susceptible to influenza, but the elderly and children are more vulnerable. Elderly individuals (those 65 and older) with weakened immune systems are more likely to develop serious flu-related comorbidities. Since 2010, influenza has affected 9.3 million to 49.0 million individuals in the U.S. alone, according to the CDC.
Additionally, almost 55,000 individuals in Canada suffered influenza in 2018, according to the Infection Prevention and Control (IPAC). Owing to the rising prevalence of influenza worldwide, there will be high demand for rapid influenza diagnostic test.
Governmental bodies in various nations are funding the development of novel rapid influenza diagnostic tests due to the increase in epidemics and pandemics over the past several years. For instance, the U.S. government granted $21.9 million to the contagious disease testing company Diassess Inc. to support the development of its ground-breaking flu diagnostic equipment for use in medical clinics and eventually in homecare. These governmental initiatives are anticipated to encourage market expansion for the market on a global level.
Every year, the onset of flu season causes an increase in antibiotic use, which raises the risk of antibiotic resistance in the body. Use of point-of-care devices helps advance healthcare toward value-based care by delivering conclusive data and increasing confidence in how the patient should be handled. Rapid diagnostic tests for influenza offer a quick turnaround, with some giving results in under 15 minutes. Thus, the adoption of quick influenza diagnostic tests aids in preventing the overuse of antibiotics as well as the underlying causes of rising bacterial resistance and its negative effects. Such advantageous features continue to play a significant role in the market expansion.
The global market is thus likely to show high growth over the coming years at a CAGR of 8.6% and reach a global market size of US$ 2.4 Bn by 2033.
“Early Detection and Prevention of Influenza”
Influenza is a highly transmissible infection that spreads through an infected person's coughs and sneezes. Type A, Type B, and Type C influenza viruses are the three main strains that affect people. The rapid diagnostic test for influenza aids patients in the early detection of the flu, a respiratory illness brought on by a virus that spreads through the coughs and sneezes of an infected person and which can result in major health issues and even death. The best method for preventing the flu and treating it right away is early detection.
“Technological Advancements in Diagnostic Equipment”
Rapid molecular assays are a novel class of highly sensitive and specific molecular diagnostic tests for the diagnosis of influenza that have emerged in recent years. The ability to identify respiratory viruses has been substantially enhanced by the use of RT-PCR and nucleic acid labelling detection assays. Furthermore, the fundamental goal of molecular diagnostics for influenza is to identify specific known pathogens using NATs (nucleic acid tests). NATs are superior to other available diagnostic equipment in a number of ways. They do not function on the survival of the target microbe and can deliver results in a clinically appropriate time frame. They are more capable of identifying low amounts of all known influenza viruses in clinical specimens.
“Growing Awareness of Benefits of Early Diagnosis”
Another factors driving the demand for rapid influenza diagnostic tests is the growing understanding of the importance of early viral disease identification among the global population. In an effort to minimize and eventually eliminate disease-related mortality, organizations are taking initiatives to encourage early detection. Making critical medical decisions about support and treatment is aided by early diagnosis for both patients and medical personnel. Receiving an appropriate diagnosis as soon as possible after recognizing cognitive symptoms linked to a medical condition has many advantages.
“The False Negative Results Could Hamper the Growth”
Sensitivity and specificity are the main factors that affect the outcomes of rapid influenza diagnostic kits. The main factor contributing to the test's complexity is the antigenic variety of influenza viruses. The final test findings may be impacted because of the sensitivity and specificity of diagnostic testing for influenza can differ. Due to the higher incidence of false-negative results than false-positive results, particularly in influenza season's peak, demand for rapid influenza diagnostic tests is somewhat restricted.
“Stringent Guidelines”
Market restrictions can be a result of strict regulatory guidelines for new diagnostic tests approval. Global regulatory standards, cGMP and inspection, and supply-chain security concerns across emerging nations have a negative effect on the accessibility and pricing of final products, which has a negative impact on the market growth for rapid influenza diagnostic tests.
Why is the U.S. Market Booming?
“High Occurrence of Infectious Disease”
The U.S. is expected to hold around 31.1% market share in the global rapid influenza diagnostic tests market at the end of 2023.
Due to rising hospitalization and influenza prevalence, the U.S. dominated the North American market for rapid influenza diagnostic tests. Over the forecast period, it is anticipated that the U.S. will exhibit similar market trends. Additionally, the U.S. has a major market share in the North American region due to its large patient population.
Will the Germany Be a Lucrative Market for the Manufacturers?
“Presence of Key Players”
With a 5.7% market share, Germany will hold a fair amount of share in global market at the end of 2023.
Germany holds the majority of market share in Europe for rapid influenza diagnostic tests. This dominance is attributable to a number of factors, including an increase in influenza prevalence, supportive government initiatives, the presence of key players, and advanced facilities in the nation.
How is Japan Emerging as a Prominent Market for Rapid Influenza Diagnostic Tests?
“Rising Prevalence of Neurodegenerative Diseases”
Japan is estimated to hold market share of about 6.0% of the global rapid influenza diagnostic tests market in 2023.
Due to its well-developed healthcare system, favourable laws and insurance, various organizations, and numerous foreign companies, Japan is a growing market for quick influenza diagnostic tests. The development of the country's market for influenza diagnostics is also largely related to the expansion of research into diagnostic technologies for influenza. Major reasons contributing to the market's expansion in Japan include an increase in influenza cases, an ageing population, a rise in the demand for quick disease diagnoses, and a growing concentration of significant suppliers in the diagnostics market.
Which Principle Segment is Driving Growth of the Global Market?
“Better Efficacy than Other Lab Assays”
Immunochromatographic assays segment is expected to hold highest share of around 64.1% of the product segment by the end of 2023.
Excellent sensitivity and superior specificity in comparison to other laboratory immunoassays are the main characteristics that encourage segment growth. Several ICT tests based primarily on the detection of several parasite antigens (and antibodies in certain assays) have been developed recently, with promising findings for the diagnosis of parasitic infections. Researchers have recently evaluated ICT kits for the diagnosis of a number of parasitic diseases.
Which Test Type is Expected to Dominate the Global Market?
“Advantages of Influenza A+B Test”
Influenza A+B test segment dominated the global market share in 2022 and is expected to hold a largest market value of US$ 832.6 Mn by 2023.
Due to advantages including ease of use and quick diagnosis, the Influenza A+B test is anticipated to continue increasing at a rapid rate and to hold a sizable portion of the market share in the future.
Which Sample Type is Expected to Dominate the Global Market?
“Benefit of Nasopharyngeal Swabs”
Nasopharyngeal Swab segment is expected to hold the larger share of about 30.8% by the end of 2023.
For viral isolation or quick diagnosis of influenza viruses, nasopharyngeal specimens frequently generate higher yields than nasal or throat swab specimens.
Which End User is Expected to Emerge as a Market Leader in the Future?
“Increasing Number of Office Settings Worldwide”
Office based settings segment is expected to hold the larger share of about 23.0% by the end of 2023 globally.
Due to the rising prevalence of infectious diseases and the expanding use of rapid diagnostic testing devices, the market is expected to expand. Along with the growing number of tests as a result of the ongoing rise in the number of influenza patients and independent office settings.
The market for quick influenza diagnostic tests is categorised as a consolidated market. With the launch of new products to diversify their product offerings and customer bases, companies remain in control of the market for rapid influenza diagnostic tests. In order to expand their products to different nations, they are also focusing on obtaining regulatory permissions.
Key instances include :
| Attribute | Details |
|---|---|
|
Forecast Period |
2023-2033 |
|
Historical Data Available for |
2013-2022 |
|
Market Analysis |
USD Million for Value |
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Report Coverage |
|
|
Key Companies’ Profile |
|
|
Customization & Pricing |
Available upon Request |
Principle:
Test Type:
Sample Type:
End User:
Region:
To know more about delivery timeline for this report Contact Sales
The global market stands at US$ 952.1 Mn in 2022.
Sales of the market are set to witness growth at a CAGR of 8.6% and be valued at around US$ 2.4 Bn by 2033.
Demand for the market increased at a 7.6% CAGR from 2013 to 2022.
U.S., Canada Germany, Japan and Australia accounted for the major share in the global market as of year 2022, holding around 56.0% market share.
The U.S. expected to account for around 31.1% share of the global market in 2023.
Latin America accounts for around 5.3% share of the global market in 2023.
Japan market is expected to hold a share of about 6.0% in the global rapid influenza diagnostic tests market in 2023.
With a 5.7% market share, Germany will hold a fair amount of share in global market at the end of 2023.
UK market is expected to grow over a CAGR of 5.5% over the forecast duration.
India is expected to grow over a CAGR of 11.6% over the forecast duration.
